___

• [1] Y. Batmani, H. Khaloozadeh, Multi objective optimization of drug regimens in cancer chemotherapy using a PK-PD model, 19th Iranian Conference on Electrical Engineering, (2011), 1-1.
• [2] A. Floares, C. Floares, M. Cucu, L. Lazar, Adaptive neural networks control of drug dosage regimens in cancer chemotherapy, Proceedings of the International Joint Conference on Neural Networks, 1 (2003), 154-159.
• [3] M. M. Hadjiandreou, G. D. Mitsis, Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design, IEEE Trans. Biomed. Eng., 61(2) (2014), 415-425.
• [4] A. Petrovski, J. McCall, B. Sudha, Multi-objective optimization of cancer chemotherapy using swarm intelligence, AISB Symposium on Adaptive and Emergent Behaviour and Complex Systems, UK Society for AI, (2009).
• [5] A. Petrovski, J. McCall, Multi-objective optimisation of cancer chemotherapy using evolutionary algorithms, International Conference on Evolutionary Multi-Criterion Optimization, Springer, Berlin, Heidelberg, (2001).
• [6] J. McCall, Genetic algorithms for modelling and optimisation, J. Comput. Appl., 184(1) (2005), 205-222.
• [7] H. Khaloozadeh, Y. Pedram, H. S. Fatemeh, The optimal dose of CAF regimen in adjuvant chemotherapy for breast cancer patients at stage IIB, Math. Biosci., 213(2) (2008), 151-158.
• [8] T. Ajayi, S. Hosseinian, A. J. Schaefer, C. D. Fuller, Combination Chemotherapy Optimization with Discrete Dosing, arXiv preprint, (2021).
• [9] A. Petrovski, An application of genetic algorithms to chemotherapy treatment, Ph.D. Thesis, Robert Gordon University, 1998.
• [10] S. L. Thomson, G. Ochoa, The Local Optima Level in Chemotherapy Schedule Optimisation, European Conference on Evolutionary Computation in Combinatorial Optimization (Part of EvoStar), Springer, Cham, (2020).
• [11] K. Kassara, A unified set-valued approach to control immunotherapy, SIAM J. Control Optim., 48 (2009), 909-924.
• [12] M. Serhani, H. Essaadi, K. Kassara, A. Boutoulout, Control by viability in a chemotherapy cancer model, Acta Biotheor., 67 (2019), 177-200.
• [13] K. Kassara, A. Moustafid, Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method, Math. Biosci., 231 (2011), 135-143.
• [14] A. Moustafid, General Anti-Angiogenic Therapy Protocols with Chemotherapy, Int. J. Math. Model. Computations, 11(3) (2021).
• [15] A. Moustafid, General chemotherapy protocols, J. Appl. Dynamic Syst. Control, 4 (2021), 18-25.
• [16] L. Boujallal, O. Balatif, M. Elhia, A set-valued approach applied to a control problem of tuberculosis with treatment, IMA J. Math. Control Inf., 38 (2021), 1010-1027.
• [17] M. Elhia, L. Boujallal, M. Alkama, O. Balatif, M. Rachik, Set-valued control approach applied to a COVID-19 model with screening and saturated treatment function, Complexity, (2020).
• [18] L. Boujallal, M. Elhia, O. Balatif, A novel control set-valued approach with application to epidemic models, J. Appl. Math. Comput., 65 (2021), 295-319.
• [19] J. P. Aubin, Dynamic Economic Theory: A Viability Approach, Springer, Berlin, 1997.
• [20] A. Iliadis, Optimizing drug regimens in cancer chemotherapy, Basic Clin. Pharmacol. Toxicol., 96(3) (2005), 269-270.